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Abstract 
Background: The role of miRNAs in the pathogenesis and determining the phenotypes of asthma is not fully eluci-
dated. miR-146a has been previously shown to suppress inflammatory responses in different cells. In this study, we 
investigated the functions of miR-146a in human bronchial epithelial cells (HBECs) in association with neutrophilic, 
eosinophilic, and paucigranulocytic phenotypes of asthma.
Methods: Bronchial brushing specimens and brochial mucosal biopsy samples were collected from adult patients 
with asthma and from age- and gender-matched non-asthmatic individuals. The expression of miR-146a in bronchial 
brushing specimens, bronchial biopsy tissue sections or cultured primary bronchial epithelial cells was analyzed by 
RT-qPCR or by in situ hybridization. The expression of direct and indirect miR-146a target genes was determined by 
RT-qPCR or ELISA. The migration of neutrophils was studied by neutrophil chemotaxis assay and flow cytometry. For 
statistical analysis, unpaired two-way Student’s t test, one-way ANOVA or linear regression analysis were used.
Results: Reduced expression of miR-146a was found in bronchial brushing specimens from asthma patients as com-
pared to non-asthmatics and irrespective of the phenotype of asthma. In the same samples, the neutrophil attracting 
chemokines IL-8 and CXCL1 showed increased expression in patients with neutrophilic asthma and increased IL-33 
expression was found in patients with eosinophilic asthma. Linear regression analysis revealed a significant negative 
association between the expression of miR-146a in bronchial brushings and neutrophil cell counts in bronchoalveolar 
lavage fluid of patients with asthma. In bronchial biopsy specimens, the level of miR-146a was highest in the epithe-
lium as determined with in situ hybridization. In primary conventional HBEC culture, the expression of miR-146a was 
induced in response to the stimulation with IL-17A, TNF-α, and IL-4. The mRNA expression and secretion of IL-8 and 
CXCL1 was inhibited in both stimulated and unstimulated HBECs transfected with miR-146a mimics. Supernatants 
from HBECs transfected with miR-146a had reduced capability of supporting neutrophil migration in neutrophil 
chemotaxis assay.
Conclusion: Our results suggest that decreased level of miR-146a in HBECs from patients with asthma may contrib-
ute to the development of neutrophilic phenotype of asthma.
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Background
Asthma affects up to 300 million people worldwide [1]. 
Patients with asthma suffer from bronchoconstriction 
and increased mucus production in the airways that 
results in symptoms like coughing, wheeze and chest 
tightness [2, 3]. As asthma is a highly heterogeneous dis-
ease, attempts have been made to define asthma pheno-
types and/or endotypes on the basis of involved immune 
cells or molecular processes, respectively [4–6]. As one 
option, this allows categorization of asthmatics into 
eosinophilic, neutrophilic, mixed granulocytic and pauci-
granulocytic asthma phenotypes [4, 5]. The eosinophilic 
phenotype is characterized by the presence of eosinophils 
in the lung, is frequently associated with increased Th2 
responses, involvement of type 2 innate lymphoid cells 
(ILC2) and increased cytokines IL-4, IL-5 and IL-13 [7, 
8]. Patients with paucigranulocytic asthma tend to have 
fewer overall immune cells in the airways, as measured in 
the bronchoalveolar lavage fluid (BALF) [4, 5]. In neutro-
philic asthma, neutrophil chemoattractants are secreted 
by bronchial epithelial cells and fibroblasts, for example 
in response to IL-17 secretion from Th17 cells or ILC3 [9, 
10]. Independent from phenotype, airways of all asthma 
patients are influenced by chronic inflammation, which 
also leads to the changes in genes affecting cell prolifera-
tion, such as HBEGF and FGF2 and eventually, airway 
remodeling may take place [1–3].
Inhaled glucocorticosteroids represent hallmark of 
asthma management, often together with other control-
ler medicines that include β2-agonists, theophylline, 
antileukotrienes and anticholinergics [11–13]. In addi-
tion, several biologics have become available recently for 
severe asthma and more will be introduced in the future 
[6, 14]. However, because these treatment options are not 
always applicable and occasionally fail to prevent asthma 
exacerbations, there is still a need for better understand-
ing of the molecular background of asthma to achieve 
more effective treatment [15, 16].
miRNAs are short endogenous RNAs capable of reg-
ulating gene expression through binding their target 
mRNA via partial complementarity, which leads to inhi-
bition of the translation or mRNA degradation [17–19]. 
The majority of protein coding genes in human cells and 
most biological processes, including innate and adap-
tive immune responses influencing the development of 
asthma, are regulated by miRNAs [20, 21]. Previous stud-
ies have shown that miR-146a has important role in the 
suppression of inflammatory responses in different cell 
types [22–24] and therefore is involved in modulation of 
immune responses. In line with that, we have previously 
shown that miR-146a inhibits inflammatory responses 
in human primary keratinocytes and in a mouse model 
of atopic dermatitis [25, 26]. One of the main target 
genes of miR-146a is IL-1 receptor-associated kinase 1 
(IRAK1) [27], which suppression leads to reduced activ-
ity of the nuclear factor (NF)-κB pathway and inhibition 
of numerous pro-inflammatory chemokines, including 
C–X–C Motif Chemokine Ligand (CXCL)1 and IL-8 
[26, 28]. A recent genome-wide association study of a 
broad allergic disease phenotype (GWAS; n = 360,838) 
identified MIR3142–MIR146A as a shared risk loci of 
asthma, hay fever and atopic dermatitis [29]. The capac-
ity of miR-146a to inhibit the expression of pro-inflam-
matory chemokines IL-8 and CCL5 [28], to augment 
the anti-inflammatory effect of glucocorticosteroids [30] 
in human lung alveolar epithelial cell line A549, and to 
inhibit neutrophil elastase-induced gene MUC5AC 
in immortalized human bronchial epithelial cell line 
16HBE [31] has been formerly shown. Very recently, the 
increased expression of miR-146a in cultured commer-
cial human airway or bronchial epithelial cells (HBECs) 
was reported [30]. However, no data about miR-146a 
expression in airway epithelial cells of asthma patients is 
available, as well as the potential influence of miR-146a 
on the development or contribution to the heterogeneity 
of asthma has not been studied before.
Here we analyzed the expression of miR-146a and 
selected genes either known to be influenced by miR-
146a or associated with Th2 or Th1 responses in brush 
biopsy specimens from patients with asthma. In addition, 
the expression regulation and function of miR-146a in 
the modulation of molecular processes associated with 
asthma was studied in primary conventional HBEC cul-
tures. Our results reveal that reduced expression of miR-
146a in HBECs may lead to cellular processes that skew 
immune responses towards neutrophilic one and thus 




Bronchial brushing samples used for RNA isolation were 
obtained from 30 adult patients with asthma in stable 
phase and from 11 age- and gender-matched non-asth-
matic individuals from the Department of Pulmonology, 
the Jagiellonian University Medical College (Krakow, 
Poland). The diagnosis of asthma was made according to 
Global Initiative for Asthma (GINA) guidelines. Asthma 
patients were categorized into eosinophilic, neutro-
philic and paucigranulocytic inflammatory phenotypes 
based on the number of granulocytes present in BALF. 
Bronchial mucosal biopsy samples for in  situ hybridiza-
tion were collected from 3 adult patients with asthma 
and 2 non-asthmatic individuals from the Tartu Univer-
sity Hospital (Tartu, Estonia). The study was approved 
by the Research Ethics Committees of the Jagiellonian 
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University Medical College and the University of Tartu. 
Each participant provided written informed consent. 
Additional information regarding recruited individuals is 
provided in Table 1 and Additional file 1.
Cell culture, stimulation and transfection of HBECs
HBECs were isolated from bronchial biopsies by ini-
tial short-term pronase (Roche, Basel, Switzerland) and 
DNase (Sigma-Aldrich, USA) digestion. In total, cell 
lines were isolated from 1 asthma and 4 control subjects. 
Primary HBECs were cultured as monolayer in sup-
plemented BEGM™ (Bronchial Epithelial Cell Growth 
Medium, Lonza, Basel, Switzerland) medium. For stimu-
lation, IFN-γ (final concentration 20 ng/ml, eBiosciences, 
USA), TNF-α (20 ng/ml, Biolegend, USA), IL-17A (10 ng/
ml, Peprotech, UK), IL-22 (20 ng/ml, Peprotech, UK) and 
IL-4 (40 ng/ml, Peprotech, UK) were used. For transfec-
tions, miRIDIAN microRNA Mimic Negative Control 
#1 (Dharmacon™, USA) or miRIDIAN microRNA hsa-
miR-146a-5p mimic (Dharmacon™, USA) were trans-
fected using MIRFECT (RNAexact, Estonia) according to 
manufacturer’s protocol. Additional information can be 
found in Additional file 1.
RNA isolation, cDNA synthesis and RT‑qPCR
For RNA isolation Qiazol (Qiagen, Germany) and Total 
RNAzole out Mini kit (A&A Biotechnology, Poland) 
were used according to the manufacturer’s instructions. 
To analyze miRNA expression, either  TaqMan® Micro-
RNA Assays (Life Technologies, California, USA) and 
5× HOT  FIREPol® Probe qPCR Mix Plus (ROX) (Solis 
BioDyne, Tartu, Estonia) or miScript II RT Kit, miS-
cript SYBR Green PCR Kit and Hs_miR-146a_1 miS-
cript Primer Assay (cat. MS00003535) by Qiagen were 
used according to the manufacturer’s protocols. For 
normalization let-7a and ΔΔCt calculation were used. 
For mRNA RT-qPCR, cDNA was synthesized using 
oligo-dT (TAG Copenhagen, Denmark), RevertAid 
Reverse Transcriptase (Thermo Scientific) followed by 
qPCR with 5× HOT FIREPol EvaGreen qPCR Super-
mix (Solis BioDyne, Estonia). Target gene expression 
was normalized to EEF1A1 expression using ΔΔCt cal-
culation. Additional information is provided in Addi-
tional file 1.
ELISA and neutrophil chemotaxis assay
Supernatants from HBECs transfected with miRNA 
mimics and stimulated with cytokines were used for 
ELISA and neutrophil chemotaxis assay. ELISA MAX™ 
Deluxe Set (BioLegend, 431504) for IL-8 and human 
CXCL1/GRO alpha DuoSet ELISA (R&D Systems, 
DY275-05) were used according to the manufactur-
ers’ instructions. For neutrophil chemotaxis assay, 
4 × 105 of primary human neutrophils were seeded on 
ThinCert cell culture inserts (3-μm pore size) (Greiner 
Bio-One, Kremsmünster, Austria) placed in 24 well 
plate containing the supernatants from HBECs. 60 min 
after incubation at 37 °C, the number of migrated neu-
trophils was analyzed by using BD LSRFortessa (BD 
Biosciences, USA) cell analyzer. More detailed informa-
tion is provided in Additional file 1.
Table 1 Clinical characteristics of studied patients
NA not applicable/available
a Eosinophilic (E), > 2% of eosinophils and < 3% of neutrophils in BALF
b Neutrophilic (N), < 2% eosinophils and > 3% neutrophils in BALF
c Paucigranulocytic (P), < 2% of eosinophils and < 3% neutrophils in BALF
d IQR, interquartile range; asthma severity stages according to GINA (Global Initiative for Asthma) classification
Characteristic All asthmatics Eosinophilica phenotype Neutrophilicb phenotype Paucigranulocyticc 
phenotype
Controls
n, (%) 30 (100) 11 (36.7) 7 (23.3) 12 (40.0) 11 (100)
Gender: male/female 16/14 4/7 5/2 7/5 7/4
Age (y), mean ± SD 45.6 ± 13.1 39.8 ± 9.5 48.1 ± 18.7 49.3 ± 11.3 52.2 ± 16.6
Duration of asthma (y), mean ± SD 15.0 ± 16.3 8.3 ± 8.0 13.9 ± 7.9 21.8 ± 22.7 NA
FEV1 % predicted 81.8 ± 24.0 86.6 ± 22.7 74.2 ± 32.9 81.9 ± 20.1 111.2 ± 9.6
FEV1 % reversibility 7.2 ± 7.2 6.5 ± 5.4 6.2 ± 5.7 8.4 ± 9.5 3.0 ± 3.5
Positive skin prick test with common 
allergens n, (%)
15 (50.0) 4 (36.4) 4 (57.1) 7 (58.3) NA
Severity of asthma, median (IQR)d 4 (1–5) 4 (2–4) 4 (2–5) 4 (1–5) NA
Inhaled glucocorticosteroids (%, aver-
age dose μg, [range])
96.6, 969 (0–4000) 100, 940 (250–2000) 100, 929 (500–2000) 91.6, 1020
(0–4000)
0
Systemic glucocorticosteroids n, (%) 7 (23.3) 1 (9.1) 4 (57.1) 2 (16.7) 0
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In situ hybridization (ISH)
ISH was performed using 10 μm sections of frozen bron-
chial mucosal biopsy specimens. Using miRCURY LNA 
miRNA ISH Buffer Set (FFPE), hsa-miR-146a-5p miR-
CURY LNA miRNA Detection probe (cat. YD00619856) 
and control probe miRCURY scrambled ISH 49  °C (cat. 
YCD0074470-BCG) were used according to the manufac-
turer’s (Qiagen) protocol. Densitometry analysis of stain-
ing in in situ hybridization images were performed with 
ImageJ software. Additional information is provided in 
Additional file 1.
Statistical analysis
For visualization and statistical analysis, GraphPad Prism 
5 (GraphPad Software Inc, USA) and unpaired two-way 
Student’s t-test, One-way ANOVA or linear regression 
analysis were used. The results were considered signifi-
cant at *P < 0.05; **P < 0.01; ***P < 0.001. For heatmapping, 
online software Morpheus (https ://softw are.broad insti 
tute.org/morph eus/) was used.
Results
The expression of miR‑146a is reduced in bronchial brush 
specimens and is in negative association with the number 
of neutrophils in the airways of patients with asthma
To assess the role of miR-146a in association with asthma, 
we first examined miR-146a expression in bronchial 
brushing samples subjected to preserving conditions 
immediately after collection and later to simultaneous 
RNA purification. The bronchial brushing samples from 
asthma patients expressed significantly less miR-146a 
when compared with non-asthmatic controls (Fig.  1a). 
When patients were subgrouped based on inflammatory 
phenotypes, we observed miR-146a downregulation in 
airway epithelial cells from patients with eosinophilic, 
neutrophilic and paucigranulocytic asthma phenotype 
as compared to non-asthmatic controls (Fig.  1b). Lin-
ear regression analysis revealed a negative relationship 
between miR-146a expression in bronchial brushings and 
neutrophil cell counts in BALF in asthmatics (Fig. 1c). No 
association was found between the expression of miR-
146a and eosinophil counts in the airways (Additional 
file  1: Figure S1A). To further analyze the expression 
and localization of miR-146a in human airways, we per-
formed ISH on bronchial biopsy sections. The strongest 
miR-146a staining was confined to the bronchial (Fig. 1d) 
and bronchiolar epithelium (Additional file  1: Figure 
S1C), suggesting that in the lungs, miR-146a is mainly 
expressed in the bronchial epithelium. No significant 
difference in the expression level of miR-146a between 
the samples from asthma patients and controls were 
observed by ISH (Additional file  1: Figure S1B). Hema-
toxylin and eosin staining revealed an increased thickness 
of the basal lamina (Fig. 1e) and epithelial shedding (data 
not shown) in samples from the patients with asthma. In 
conclusion, we show that miR-146a is expressed in the 
epithelium layer of lung tissue and is reduced in airway 
epithelial cells from patients with asthma irrespective of 
lower airway inflammatory phenotype.
The expression of miR‑146a‑influenced chemokines 
is increased in the airway epithelial cells from patients 
with neutrophilic asthma phenotype
As the miR-146a level was reduced in the airway epithe-
lial cells from patients with asthma, we next analyzed 
mRNA expression of miR-146a indirect (CXCL1 and 
IL-8) [26, 28] and direct (IRAK1) [27] target genes in 
the same samples. In addition, to evaluate the relevance 
of our findings, we assessed the expression of genes pre-
viously associated with Th2 type immune responses, 
including IL-33 [32] and IL-4 receptor (IL-4R) [33], and 
the interferon-response genes associated with Th1 type 
immune responses, such as interferon regulatory fac-
tor 1 (IRF1) and IFITM1. Among these genes, only the 
expression of IL-33 was detected to be increased when 
all asthma patient samples were included to analysis 
(Additional file  1: Figure S1D). When the patients were 
subdivided by inflammatory phenotypes, the upregulated 
expression of miR-146a-influenced chemokines IL-8 
and CXCL1 (Fig.  2a) as well as higher expression lev-
els of IL-4R (Fig. 2b) and interferon response gene IRF1 
(Fig.  2c) were detected in airway epithelial cells from 
patients with neutrophilic asthma. The expression of 
IL-33 was significantly higher in eosinophilic asthmatics 
when compared to non-asthmatics (Fig.  2b). miR-146a 
direct target IRAK1 did not differ between non-asthmat-
ics and asthma patients in any analysis (Fig.  2a, Addi-
tional file 1: Figure S1D). Furthermore, linear regression 
analysis did not reveal any association between miR-146a 
expression and mRNA levels of tested indirect and direct 
genes (data not shown). Taken together, we detected that 
airway epithelial cells from asthma patients with neutro-
philic phenotype had expected increased expression of 
IL-8 and CXCL1 while asthmatics with eosinophilic phe-
notype had an enhanced expression of IL-33.
Pro‑inflammatory cytokines induce the expression 
of miR‑146a in HBECs
To understand how miR-146a expression is regulated 
in the airway epithelial cells, we stimulated primary 
cultured HBECs from healthy donors with cytokines 
associated with asthma pathogenesis, including IFN-γ, 
TNF-α, IL-17A, IL-22 and IL-4 [34, 35]. The expression 
of miR-146a was strongly induced by pro-inflammatory 
cytokines TNF-α and IL-17A, and with less extent by 
IL-4 (Fig.  3a). The highest increase in the expression of 
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miR-146a was present in cells co-stimulated by TNF-α 
and IL-17A (Fig. 3a). No influence of IFN-γ and IL-22 on 
miR-146a level was detected. To evaluate the relevance of 
this result, we measured the expression of the same set 
of protein coding genes in stimulated HBECs that was 
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Fig. 1 The expression of miR-146a is downregulated in epithelial cells from airway biopsies of patients with asthma. a–c Relative expression 
of miR-146a in bronchial brushing specimens from patients measured by RT-qPCR. Data represent mean ± SEM. a Unpaired t-test, ***P < 0.001. 
b Patients were categorized into inflammatory phenotypes based on BALF cell percentages: eosinophilic (E), > 2% of eosinophils and < 3% of 
neutrophils in BALF; neutrophilic (N), < 2% eosinophils and > 3% neutrophils in BALF; paucigranulocytic (P), < 2% of eosinophils and < 3% neutrophils 
in BALF). One-way ANOVA, *P < 0.05. c Linear regression analysis between miR-146a expression in asthmatic bronchial brushings (data presented 
on log2 scale) and neutrophil percentage among non-epithelial BALF cells. 95% confidence interval (CI) of the regression line is shown as dotted 
line. d, e 10 μm sections of frozen bronchial biopsy samples were subjected to in situ hybridization (d) or hematoxylin and eosin staining (e), 
bar = 50 μm. d Blue color shows the expression of miR-146a. Black dashed line indicates the outer border of the epithelium layer in the specimen. 
Red dashed line indicates the outer border of the basal lamina. One asthmatic and non-asthmatic sample representative of 3 and 2 subjects, 
respectively
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mRNA level, the expression of IL-8 was induced by all 
cytokines analyzed (Fig.  3b). However, at protein level, 
IL-8 was induced in response to TNF-α, IL-17A and IL-4 
and most strongly by co-stimulation with TNF-α and 
IL-17A (Fig. 3c), which was similar to the changes in the 
expression of miR-146a (Fig.  3a) and CXCL1 (Fig.  3b, 
c). Out of the studied interferon response genes, IRF1 
was highly induced in response to all cytokines ana-
lyzed, however, the expression of IFITM1 changed only 
in response to stimulation with IFN-γ, IL-22 or IL-4 
(Fig.  3b). As chronic inflammation influnces cell prolif-
eration associated with tissue remodeling, we also ana-
lyzed the expression of Heparin-binding EGF-like growth 
factor (HBEGF) and Fibroblast Growth Factor 2 (FGF2). 
As shown on Fig.  3b, HBEGF expression was induced 
in response to all studied pro-inflammatory cytokines 
except for IL-22 and IL-4 stimulation and FGF2 expres-
sion was increased by all cytokines but IL-22. The 
expression of Th2-type inflammatory genes IL-33 and 
IL-4R were also increased in response to IFN-γ stimu-
lation (Fig. 3b), and to less extent by TNF-α. These data 
together demonstrate that several proinflammatory 
cytokines, including Th2-type cytokine IL-4, have capac-
ity to stimulate the expression miR-146a in parallel with 
inflammation-associated mediators in primary HBECs.
Overexpression of miR‑146a leads to decreased expression 
of pro‑inflammatory chemokines, diminished expression 
of airway remodeling associated growth factors 
and moderate increase in interferon response genes
To better understand the function of miR-146a in the air-
way epithelial cells, we next transfected primary HBECs 
with miR-146a and control mimics and then stimulated 
the cells with pro-inflammatory cytokines (Fig. 4). There-
after, miR-146a (Fig. 4a) and mRNA expression levels of 
the same genes that we analyzed in bronchial brushing 
samples and stimulated HBECs, were measured. As dem-
onstrated in Fig.  4b, the expression of miR-146a direct 
target gene IRAK1 was strongly inhibited in miR-146a 
transfected cells in all used conditions. Concordantly, 
IL-8 mRNA was significantly decreased in miR-146a 
transfected cells in all conditions and CXCL1 was down-
regulated when stimulated with IFN-γ, TNF-α, IL-17A 
or IL-4 (Fig.  4c). In miR-146a transfected HBECs, the 
cb
a
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Fig. 2 The expression of miR-146a-influenced chemokines is increased in brush biopsy airway epithelial cells from asthma patients with 
neutrophilic asthma phenotype. Relative mRNA expression of indicated miR-146a-influenced genes (a), genes associated with Th2 type responses 
(b) and interferon dependent genes (c) in bronchial brushing specimens from patients with asthma was measured by RT-qPCR and compared to 
the expression levels in the samples from control individuals. a–c Patients were categorized into inflammatory phenotypes based on BALF cell 
percentages: eosinophilic (E), > 2% of eosinophils and < 3% of neutrophils in BALF; neutrophilic (N), < 2% eosinophils and > 3% neutrophils in BALF; 
paucigranulocytic (P), < 2% of eosinophils and < 3% neutrophils in BALF). Data represent mean ± SEM. One-way ANOVA, *P < 0.05, **P < 0.01
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expression of IRF1 was induced in unstimulated cells and 
IFITM1 expression was increased in unstimulated condi-
tions, as well as in cells stimulated with TNF-α, IL-17A 
or IL-4 (Fig.  4d). No effect on Th2 related genes IL-33 
and IL-4R was observed by overexpression of miR-146a 
in HBECs (data not shown). The expression of growth 
factors related to tissue remodelling was also influenced 
by overexpression of miR-146a: HBEGF was reduced in 
most of the conditions and FGF2 in the presence of IL-
17A (Fig.  4e). When transfected HBECs were costimu-
lated with TNF-α and IL-17A, miR-146a overexpression 
led to the significant suppression of IL-8 and increase 
in IFITM1 expression (Additional file 1: Figure S2B, C). 
Decreased expression of IL-8 and CXCL1 in cells trans-
fected with miR-146a was confirmed on protein level 
by measuring concentration of these chemokines in the 
cell culture supernatants (Fig.  4f and Additional file  1: 
Figure S2E). Together these data demonstrate that miR-
146a has capacity to modulate inflammatory responses of 
HBECs via inhibiting the expression of pro-inflammatory 
chemokines IL-8 and CXCL1 and moderately upregulat-
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Fig. 3 Pro-inflammatory cytokines induce the expression of miR-146a in HBECs. Cultured HBECs were stimulated with shown cytokines for 48 h 
or left unstimulated (US). a Relative expression of miR-146a expression was measured by RT-qPCR and is shown in comparison with US cells. b 
Heatmap of relative mRNA expression levels of indicated genes measured by RT-qPCR. Log2 values of fold changes were mean-centered for each 
gene separately. c IL-8 and CXCL1 protein levels from the supernatants of cytokine stimulated HBECs measured by ELISA. a, c Data represent 
mean ± SEM. a–c Unpaired t-test, *P < 0.05, **P < 0.01, ***P < 0.001
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miR‑146a inhibits the expression of secretable factors 
needed for neutrophil migration
Since the expression of IL-8 and CXCL1, known to 

































































































































































































































































Fig. 4 miR-146a inhibits the expression of pro-inflammatory chemokines IL-8 and CXCL1 and moderately upregulates interferon response genes. 
HBECs were transfected with miR-146a or control mimic and 24 h later stimulated with indicated cytokines or left unstimulated (US) for 48 h until 
harvesting. Relative miR-146a expression (a) and mRNA (b–e) expression was measured by RT-qPCR. (f) Protein levels of IL-8 and CXCL1 from the 
supernatants of transfected and stimulated HBECs were measured by ELISA. Data represent mean ± SEM. Unpaired t-test, *P < 0.05, **P < 0.01, 
***P < 0.001
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miR-146a transfected HBECs, we next studied whether 
miR-146a has an effect on neutrophil migration using 
cell supernatants from HBECs transfected with miR-
146a or control mimic and stimulated with TNF-α, IFN-
γ, IL-17A or IL-4. Stimulation of HBECs with TNF-α or 
IL-17A led to enhanced secretion of factors attracting 
neutrophils while overexpression of miR-146a in these 
conditions resulted in the suppression of neutrophil 
migration (Fig.  5a). The highest number of neutrophils 
was found in the supernatants from control mimic trans-
fected and TNF-α + IL-17A stimulated HBECs, however, 
the effect of miR-146a was not significant in these con-
ditions (Additional file  1: Figure S2F). The stimulation 
of HBECs with IFN-γ or IL-4 did not have an effect on 
the number of migrating neutrophils, neither was an 
influence of miR-146a in the presence of these cytokines 
observed (Fig. 5b). These results indicate that miR-146a 
has capacity to suppress the production of chemoattract-
ants needed for neutrophil migration.
Discussion
Asthma is a heterogeneous disorder, which is not always 
well controlled. Hence, there is an unmet need for bet-
ter understanding of the mechanisms underlying the 
phenotypic diversity of asthma. In this study, we report 
significantly lower miR-146a expression in brushing 
biopsy airway epithelial cells from patients with asthma 
and a negative association between the reduced miR-
146a expression and the number of neutrophils pre-
sent in the airways. In the bronchial biopsy specimens, 
miR-146a was most highly expressed in the epithelium 
layer as determined by ISH. Further analyses showed 
expected excessive expression of neutrophil attracting 


















































































































Fig. 5 miR-146a inhibits the expression of secretable factors needed for neutrophil migration. Neutrophil chemotaxis assay was performed using 
supernatants of HBECs transfected with miR-146a or control mimic and stimulated with indicated cytokines as in Fig. 4. Migrated neutrophils were 
counted by flow cytometry. Data represent mean ± SEM. Unpaired t-test, *P < 0.05, **P < 0.01, ***P < 0.001
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with neutrophilic asthma, while eosinophilic subgroup 
showed increased IL-33 expression. In cultured HBECs, 
the expression of miR-146a was induced in response to 
stimulation with pro-inflammatory cytokines character-
istic of Th17 and Th2 driven inflammation. Overexpres-
sion of miR-146a in HBECs inhibited the expression of 
neutrophil attracting chemokines IL-8 and CXCL1 and 
reduced the number of migrating neutrophils in neutro-
phil chemotaxis assay. Together, our results indicate that 
reduced expression of miR-146a in airway epithelial cells 
from asthma patients may contribute to the development 
of neutrophilic phenotype of asthma.
Several studies have reported dysregulation of miRNAs 
in airway epithelial cells from asthmatics and suggest that 
these changes may contribute to the regulation of inflam-
matory responses and airway remodeling [37–40]. How-
ever, to our knowledge, our study is the first describing the 
downregulated expression of miR-146a in airway epithe-
lial cells of asthma patients. This finding is consistent with 
a previous study showing that patients with severe asthma 
have lower expression of miR-146a in  CD8+ and  CD4+ T 
cells [41]. However, our observation is quite unusual as 
the expression of miR-146a has been more often reported 
to be increased in site of inflammation, for example in 
keratinocytes and in the skin of patients with atopic der-
matitis and psoriasis [25, 26]. Using in situ hybridization, 
we observed that miR-146a is expressed in the lung epi-
thelium and in bronchial, bronchiolar, and alveolar epi-
thelium with no difference in the relative signal intensity 
of miR-146a between asthmatic patients and controls as 
analyzed by densitometry analysis. We propose that ISH 
using only a few samples is not sufficiently quantitative 
approach, however it is a suitable method to determine 
the expression location of miR-146a in lung epithelium. 
Interestingly, although miR-146a was downregulated 
in all asthma phenotypes, the linear regression analysis 
revealed a negative association between miR-146a levels 
in bronchial brushing samples and the number of neutro-
phils in BALF fluid, which prompted us to further address 
the question about the possible influence of miR-146a on 
the development of neutrophilic asthma phenotype.
To assess the relevance of the finding of the lower 
miR-146a expression in airway epithelial cells, we also 
tested the expression of selected protein coding genes. 
Increased expression of IL-8, CXCL1, IL-4R and IRF1 in 
patients with neutrophilic asthma and enhanced IL-33 in 
samples from eosinophilic patients confirmed phenotypic 
and endotypic similarity of these subgroups. As previ-
ous studies have shown miR-146a capacity to suppress 
IL-8 and CXCL1 in other cell types [28, 42], our results 
suggest that the lower expression of miR-146a may be 
linked to enhanced production of these chemokines 
by the airway epithelial cells in asthma. Although there 
was a negative association between the miR-146a levels 
and the number of neutrophils in BALF fluid, additional 
linear regression analysis did not reveal any association 
between relative miR-146a expression and mRNA levels 
of studied indirect and direct genes (data not shown). 
Also, we did not observe significant changes in IRAK1 
levels in the samples from the patients with asthma 
regardless of the phenotype. We propose that miR-146a 
may act partially independently from IRAK1 in primary 
bronchial epithelial cells of patients with asthma, as pre-
viously demonstrated in primary human airway smooth 
muscle cells [43] and human alveolar A549 epithelial cell 
line [44]. Further studies would be needed to confirm this 
hypothesis and to  delineate additional miR-146a direct 
targets in HBECs. Taken together, these data indicate 
that miR-146a may act through more complex network of 
genes not fully described by the current study.
To better understand the expression regulation of miR-
146a, we also analyzed its level in HBECs stimulated with 
inflammatory cytokines. Similarly to keratinocytes [26], 
the expression of miR-146a was induced by TNF-α or IL-
17A and additionally with IL-4 in HBECs. Even higher 
level of miR-146a was detected following treatment with 
combination of TNF-α and IL-17A, suggesting that these 
cytokines have a synergistic effect as in airway smooth 
muscle cells [45]. In line with previous publications [46–
48], in our current study, HBECs from healthy donors 
expressed high amounts of IL-8 and CXCL1 in response 
to stimulation with TNF-α and IL-17A, as well as was 
the expression of interferon-regulated genes IFITM1 and 
IRF1 increased in response to IFN-γ. However, none of 
the used cytokines suppressed the expression of miR-
146a leaving the question about downregulation mecha-
nism in the patient samples unanswered. We propose 
that results from cell culture experiments using high 
concentrations of cytokines rather mimic processes of 
an acute inflammation, whereas patients with asthma 
had suffered from the disease on average for 15 years and 
therefore many changes in cells from bronchial brush-
ing samples may represent characteristics of chronic 
inflammation. Furthermore, it is possible that the expres-
sion of miR-146a in HBECs of patients with asthma is 
decreased because of specific gene expression regulators, 
epigenetic and/or genetic differences. More specifically, 
microRNA expression relies on correct and functional 
microRNA biogenesis machinery, which can be disturbed 
in case of disease. For example, in lung cancer patients, 
a reduced expression of Dicer has been shown, which 
potentially might be responsible for decreased levels 
of different microRNAs in cancer cells [49]. Secondly, 
microRNA expression could be dysregulated due to epi-
genetic changes occuring during development of asthma 
as it is demonstrated for airway smooth muscle cells from 
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asthmatic subjects [50]. Third possible explanation for 
downregulated miRNA expression could be genetic alter-
ations. For example, in several types of lymphomas, the 
cause for dysregulated miR-15a and miR-16-1 is a dele-
tion in 13q14 [51]. Interestingly, it has also been shown 
that in airways of healthy individuals, genes regulating 
cell cycle and immune system are less expressed with age 
and among them miR-146 family expression was signifi-
cantly decreased, further indicating that miR-146a is one 
of the tightly regulated genes in the airways [52].
Several studies have demonstrated that miRNAs, such 
as miR-155 [7, 53, 54], miR-21 [55], miR-181 [56], and 
miR-223 [57], are involved in the regulation of airway 
inflammation. Although anti-inflammatory function of 
miR-146a has been demonstrated in various cell types, 
including bronchial epithelial cell lines [28, 30, 31], the 
function of miR-146a in primary HBECs had not been 
studied before. Our study shows that the expression of 
IL-8 and CXCL1 were decreased both on mRNA and pro-
tein level in HBECs transfected with miR-146a. We also 
demonstrate a strong reduction of IRAK1 and a moder-
ate upregulation of IRF1 and IFITM1 mRNA expression 
in miR-146a-transfected HBECs. It should be noted that 
both the suppression of IL-8 and CXCL1 and increase 
of IRF1 and IFITM1 are most probably indirect effects 
of miR-146a. As no influence of miR-146a transfection 
on the expression of IL-33 and IL-4R was detected (data 
not shown), our results suggest that miR-146a does not 
influence Th2-type inflammatory responses in HBECs. 
However, our results revealed that miR-146a expression 
affects HBEGF expression in the presence of IFN-γ, TNF-
α, IL-17A or IL-4 and FGF2 in the presence of IL-17A. 
Previous publications have shown upregulated expres-
sion of HBEGF in asthmatic tissues and its involvement 
in airway remodeling [58–60], indicating that reduced 
expression of miR-146a in airways of asthmatic patients 
may also be associated with increased airway remodeling, 
however, further investigation would be necessary to 
confirm this hypothesis.
Previous publications have demonstrated that HBECs 
express high amounts of IL-8 and CXCL1 in response to 
TNF-α and IL-17A in order to recruit neutrophils into 
the airways [46–48, 57]. Several other studies have shown 
that insufficient regulation of NF-κB signaling could be 
the origin of abnormally high expressions of IL-8 [61, 
62] and CXCL1 [63], which in turn may be the potential 
cause of neutrophilic infiltration in the lower airways of 
asthma patients. As we observed a negative association 
between the relative miR-146a expression and the num-
ber of neutrophils present in the airways and reduced 
neutrophil migration towards the supernatants of HBECs 
transfected with miR-146a and stimulated with TNF-α 
or IL-17A, our data suggest that miR-146a is capable of 
inhibiting the production of neutrophil chemoattractants 
also in the airways of patients with asthma. These results 
together suggest that there is a strong link between 
reduced expression of miR-146a in airway epithelial cells 
in asthmatic patients and the development of neutro-
philic phenotype of asthma.
In addition to data indicating that reduced expression of 
miR-146a may be linked to the recruitment of neutrophils 
in asthmatic airways, our study reveals other interest-
ing asthma-related findings. In particular, we observed a 
tendency toward increased expression of IL-4R in airway 
epithelial cells from patients with neutrophilic asthma. As 
IL-4 binding with its receptor IL-4R mediates signaling 
during allergic inflammation and could rather be associ-
ated with airway eosinophilia, this result conveys certain 
controversies [64]. Nevertheless, Lavoie-Lamoureux et al. 
have demonstrated that IL-4 may also activate neutro-
phils by increasing the secretion of IL-8 and TNF-α and 
thereby providing a link between allergic, eosinophilic 
non-allergic and neutrophilic inflammation [65].
In summary, we show that miR-146a is expressed in the 
bronchial epithelium of the airways, whereas airway epi-
thelial cells from patients with asthma express less miR-
146a as compared to controls, whereas relative levels of 
miR-146a were detected to be in negative association 
with the number of neutrophils in BALF fluid. The cause 
of the reduced miR-146a expression in asthmatic air-
ways is not known, however, it may lead to the increased 
neutrophil-attracting chemokines IL-8 and CXCL1 and 
thereby contribute to the development of neutrophilic 
phenotype of asthma. Our results provide a deeper 
understanding of inflammatory processes in asthma, and 
in long-term perspective, they might contribute to new 
potential options for therapeutic interventions.
Conclusions
The current study indicates that reduced level of miR-
146a in the airway epithelial cells of the patients with 
asthma may lead to the development of neutrophilic 
phenotype of asthma. miR-146a may have potential as a 
novel therapeutic molecule in the modulation of immune 
responses in asthma.
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